Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Treating Hepatitis C in Pakistan. Strategies to Avoid Resistance to Antiviral Drugs

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

We will determine how best to manage the hepatitis C virus (HCV) epidemic in Pakistan by measuring effectiveness of Pakistan-government sponsored current therapies, emergence of viral resistance, consequences of infection (chiefly liver cancer) and through developing models, based on incidence data, determine the proportion of people who need curative treatment to eliminate HCV, and assess whether targeting can optimise this.

Who May Be Eligible (Plain English)

Who May Qualify: - Adults over 18yrs old - Willing to undergo hepatitis C testing - Able and willing to give willing to sign a consent form - Willing to return in 12 months time for repeat testing - Resident in area and not planning to leave the region Who Should NOT Join This Trial: - Unwilling to give consent - Unwilling or unable to undergo the necessary procedures - Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol. - Co-morbidities limiting life expectancy to less than 12 months Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adults over 18yrs old * Willing to undergo hepatitis C testing * Able and willing to give informed consent * Willing to return in 12 months time for repeat testing * Resident in area and not planning to leave the region Exclusion Criteria: * Unwilling to give consent * Unwilling or unable to undergo the necessary procedures * Clinically significant illness (other than HCV) or other major medical condition that may interfere with the subject's treatment, assessment or compliance with protocol. * Co-morbidities limiting life expectancy to less than 12 months

Treatments Being Tested

DIAGNOSTIC_TEST

HCV RNA (PCR)

We will test HCV positive patients after treatment to observe if they achieve SVR

DIAGNOSTIC_TEST

HCV Antibody test (Point of care)

HCV antibody test used to establish if patients have had or are actively infected with HCV

DIAGNOSTIC_TEST

AST/ALT and platelets measurement

AST/ALT and platelets to determine APRI score

Locations (1)

Aga Khan University
Karachi, Pakistan